We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

178 hedge funds and large institutions have $1.56B invested in Edgewise Therapeutics in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 88 increasing their positions, 39 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 39

2.23% more ownership

Funds ownership: 110.64%112.87% (+2.2%)

7% less funds holding

Funds holding: 192178 (-14)

20% less funds holding in top 10

Funds holding in top 10: 108 (-2)

27% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 41

33% less call options, than puts

Call options by funds: $775K | Put options by funds: $1.15M

33% less capital invested

Capital invested by funds: $2.32B → $1.56B (-$764M)

Holders
178
Holders Change
-14
Holders Change %
-7.29%
% of All Funds
2.34%
Holding in Top 10
8
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
30
Increased
88
Reduced
39
Closed
41
Calls
$775K
Puts
$1.15M
Net Calls
-$374K
Net Calls Change
-$29.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$12.1M +$4.42M +306,847 +50%
American Century Companies
27
American Century Companies
Missouri
$10.3M +$49K +3,400 +0.4%
Morgan Stanley
28
Morgan Stanley
New York
$9.54M +$4.6M +318,717 +78%
Citigroup
29
Citigroup
New York
$9.5M +$9.38M +650,592 +876%
SI
30
Sofinnova Investments
California
$9.4M +$5.4M +374,655 +109%
PHP
31
Parkman Healthcare Partners
Connecticut
$8.49M +$3.2M +221,924 +52%
Goldman Sachs
32
Goldman Sachs
New York
$8.28M +$3.82M +265,099 +72%
Northern Trust
33
Northern Trust
Illinois
$7.9M -$54.7K -3,794 -0.6%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$7.81M +$6.56M +454,884 +324%
FCMV
35
Foresite Capital Management VI
California
$7.67M
Charles Schwab
36
Charles Schwab
California
$7.59M +$834K +57,843 +11%
EAM
37
Eventide Asset Management
Massachusetts
$7.45M
SCM
38
Sio Capital Management
New York
$7.08M +$7.78M +539,730 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$6.55M +$1.48M +102,344 +26%
OM
40
Opaleye Management
Massachusetts
$6.42M +$1.37M +95,000 +24%
Fidelity Investments
41
Fidelity Investments
Massachusetts
$6.17M +$4.11M +284,694 +153%
Aberdeen Group
42
Aberdeen Group
United Kingdom
$5.81M +$1.88M +130,294 +42%
Victory Capital Management
43
Victory Capital Management
Texas
$5.81M +$6.39M +442,837 New
TCM
44
Tang Capital Management
California
$5.65M +$1.89M +131,300 +44%
GIM
45
Granahan Investment Management
Massachusetts
$5.32M +$2.71M +187,811 +86%
EP
46
Eversept Partners
New York
$5.15M +$5.66M +392,739 New
Citadel Advisors
47
Citadel Advisors
Florida
$4.26M +$3.29M +227,971 +234%
N
48
Nuveen
North Carolina
$4.16M +$1.65M +114,593 +57%
Federated Hermes
49
Federated Hermes
Pennsylvania
$4.15M +$4.56M +316,420 +395,525%
Voloridge Investment Management
50
Voloridge Investment Management
Florida
$3.73M +$4.1M +284,551 New

EWTX Hedge Fund Activity: Q2 2025 in Review

178 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2025, worth a combined $1.56B — down 33% from $2.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of EWTX and 30 opened new positions — a net loss of 11 holders — while 39 trimmed existing stakes and 88 added.

The largest buyer was Braidwell, adding an estimated $39.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $30.8M sold.

  • 178 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2025, down from 192 in Q1 2025.
  • Funds reported $1.56B of Edgewise Therapeutics stock for Q2 2025, down 33% quarter-over-quarter.
  • 30 funds opened new Edgewise Therapeutics positions in Q2 2025 and 41 closed out, a net change of -11 holders.
  • The largest Edgewise Therapeutics buyer in Q2 2025 was Braidwell, an estimated $39.7M added.
  • The largest Edgewise Therapeutics seller in Q2 2025 was Deep Track Capital, an estimated $30.8M sold.

Based on aggregated 13F filings for Q2 2025.